TY - JOUR
T1 - Small whole heart volume predicts cardiovascular events in patients with stable chest pain
T2 - insights from the PROMISE trial
AU - Foldyna, Borek
AU - Zeleznik, Roman
AU - Eslami, Parastou
AU - Mayrhofer, Thomas
AU - Scholtz, Jan Erik
AU - Ferencik, Maros
AU - Bittner, Daniel O.
AU - Meyersohn, Nandini M.
AU - Puchner, Stefan B.
AU - Emami, Hamed
AU - Pellikka, Patricia A.
AU - Aerts, Hugo J.W.L.
AU - Douglas, Pamela S.
AU - Lu, Michael T.
AU - Hoffmann, Udo
N1 - Funding Information:
Dr. Hoffmann received Research Grants from the National Institutes of Health (U01HL092040, U01HL092022), and Siemens Medical Solutions, Heart Flow Inc., and served as a consultant for Heart Flow. Dr. Lu reports consulting fees with PQBypass and a research grant from the Nvidia Corporation Academic Program. Dr. Lu is supported by grants from the American Heart Association Precision Medicine Institute 18UNPG34030172 and the Harvard University Center For AIDS Research NIH/NIAID 5P30AI060354-14. Dr. Ferencik reports receiving a grant from the American Heart Association 13FTF16450001. The other authors have nothing to disclose.
Publisher Copyright:
© 2021, European Society of Radiology.
PY - 2021/8
Y1 - 2021/8
N2 - Objectives: The size of the heart may predict major cardiovascular events (MACE) in patients with stable chest pain. We aimed to evaluate the prognostic value of 3D whole heart volume (WHV) derived from non-contrast cardiac computed tomography (CT). Methods: Among participants randomized to the CT arm of the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE), we used deep learning to extract WHV, defined as the volume of the pericardial sac. We compared the WHV across categories of cardiovascular risk factors and coronary artery disease (CAD) characteristics and determined the association of WHV with MACE (all-cause death, myocardial infarction, unstable angina; median follow-up: 26 months). Results: In the 3798 included patients (60.5 ± 8.2 years; 51.5% women), the WHV was 351.9 ± 57.6 cm3/m2. We found smaller WHV in no- or non-obstructive CAD, women, people with diabetes, sedentary lifestyle, and metabolic syndrome. Larger WHV was found in obstructive CAD, men, and increased atherosclerosis cardiovascular disease (ASCVD) risk score (p < 0.05). In a time-to-event analysis, small WHV was associated with over 4.4-fold risk of MACE (HR (per one standard deviation) = 0.221; 95% CI: 0.068–0.721; p = 0.012) independent of ASCVD risk score and CT-derived CAD characteristics. In patients with non-obstructive CAD, but not in those with no- or obstructive CAD, WHV increased the discriminatory capacity of ASCVD and CT-derived CAD characteristics significantly. Conclusions: Small WHV may represent a novel imaging marker of MACE in stable chest pain. In particular, WHV may improve risk stratification in patients with non-obstructive CAD, a cohort with an unmet need for better risk stratification. Key Points: • Heart volume is easily assessable from non-contrast cardiac computed tomography. • Small heart volume may be an imaging marker of major adverse cardiac events independent and incremental to traditional cardiovascular risk factors and established CT measures of CAD. • Heart volume may improve cardiovascular risk stratification in patients with non-obstructive CAD.
AB - Objectives: The size of the heart may predict major cardiovascular events (MACE) in patients with stable chest pain. We aimed to evaluate the prognostic value of 3D whole heart volume (WHV) derived from non-contrast cardiac computed tomography (CT). Methods: Among participants randomized to the CT arm of the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE), we used deep learning to extract WHV, defined as the volume of the pericardial sac. We compared the WHV across categories of cardiovascular risk factors and coronary artery disease (CAD) characteristics and determined the association of WHV with MACE (all-cause death, myocardial infarction, unstable angina; median follow-up: 26 months). Results: In the 3798 included patients (60.5 ± 8.2 years; 51.5% women), the WHV was 351.9 ± 57.6 cm3/m2. We found smaller WHV in no- or non-obstructive CAD, women, people with diabetes, sedentary lifestyle, and metabolic syndrome. Larger WHV was found in obstructive CAD, men, and increased atherosclerosis cardiovascular disease (ASCVD) risk score (p < 0.05). In a time-to-event analysis, small WHV was associated with over 4.4-fold risk of MACE (HR (per one standard deviation) = 0.221; 95% CI: 0.068–0.721; p = 0.012) independent of ASCVD risk score and CT-derived CAD characteristics. In patients with non-obstructive CAD, but not in those with no- or obstructive CAD, WHV increased the discriminatory capacity of ASCVD and CT-derived CAD characteristics significantly. Conclusions: Small WHV may represent a novel imaging marker of MACE in stable chest pain. In particular, WHV may improve risk stratification in patients with non-obstructive CAD, a cohort with an unmet need for better risk stratification. Key Points: • Heart volume is easily assessable from non-contrast cardiac computed tomography. • Small heart volume may be an imaging marker of major adverse cardiac events independent and incremental to traditional cardiovascular risk factors and established CT measures of CAD. • Heart volume may improve cardiovascular risk stratification in patients with non-obstructive CAD.
KW - Cardiac volume
KW - Coronary disease
KW - Heart failure
KW - Multidetector computed tomography
UR - http://www.scopus.com/inward/record.url?scp=85099857177&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099857177&partnerID=8YFLogxK
U2 - 10.1007/s00330-021-07695-2
DO - 10.1007/s00330-021-07695-2
M3 - Article
C2 - 33501599
AN - SCOPUS:85099857177
SN - 0938-7994
VL - 31
SP - 6200
EP - 6210
JO - European radiology
JF - European radiology
IS - 8
ER -